03:42 AM EST, 03/08/2024 (MT Newswires) -- Inventiva ( IVA ) said Thursday it lifted the voluntary pause in recruitment for its phase 3 NATiV3 trial for lanifibranor.

The company previously paused patient recruitment for the study to implement recommendations from the Data Monitoring Committee, after a participant reported a potential treatment-related serious adverse event. The trial is assessing lanifibranor's effectiveness in treating non-alcoholic steatohepatitis in adult patients.

Inventiva ( IVA ) said its clinical sites in the US operating under the central IRB have resumed screening and randomization activities. The company expects to obtain approvals to restart patient recruitment in other countries over the next few weeks.

The firm expects the last patient first visit for the trial in the first half.

Price: 3.78, Change: +0.16, Percent Change: +4.42